In the absence of a submission from the holder of the marketing authorisation
panitumumab (Vectibix) is not recommended as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS (Kirsten rat sarcoma 2 viral oncogene homologue) after failure of fluoropyrimidine -, oxaliplatin -, and irinotecan - containing chemotherapy regimens.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice51KB (PDF)
- Medicine name:
- panitumumab 20mg/ml concentrate for solution for infusion (Vectibix)
- SMC ID:
- as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Date advice published
- 09 June 2008